Senior Manager, Global Value and Access

Company Overview

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA;

IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.

Immunome is seeking a Senior Manager,Global Value and Access to support globalhealtheconomics and outcomes research (HEOR) and market access activities in the US and ex-US for our oncology portfolio. This role will primarily lead the execution of HEOR studies and evidence-generation deliverables, while flexing into broader market access priorities as Immunome prepares for a potential launch of its lead asset, varegacestat.

The successful candidate will combine strong HEOR technical and project management capabilities with a practical understanding of US and ex-US payer evidence needs, value communication including field tools, and new drug launch. This is a highly visible opportunity for an individual who thrives in a fast-paced environment, learns quickly, and is eager to take on new responsibilities. The level will becommensuratewith experience;

the ideal candidate will bring enough launch exposure to add valueimmediatelywhile continuing to grow across Global Value and Access.

• Support integrated HEOR and real-world evidence strategies aligned with clinical development, medical, regulatory, and market access priorities.
• Identify evidence gaps and translate payer, health technology assessment (HTA), and business questions into fit-for-purpose research plans and analyses.
• Provide HEOR input to evidence-generation plans, value propositions, and launch- deliverables for the lead asset and broader portfolio.

• Lead real-world evidence studies, including burden of illness, treatment patterns, healthcare resource use, real-world comparative effectiveness, and epidemiology studies using claims, electronic health records, and other secondary data sources.
• Develop cost-effectiveness and budget-impact models, from early economic models that inform development and pricing strategy to submission-ready models adapted for HTA bodies ex-US.
• Conduct systematic literature reviews, indirect treatment comparisons and network meta-analyses.
• Develop and review study protocols, analysis plans, reports, abstracts, posters, and manuscripts; ensure scientific rigor, timely delivery, and clear communication of decision-relevant findings.

• Own the launch deliverables including AMCP dossier, global value dossier, budget-impact model, and cost-effectiveness models.
• Flex into launch market access work streams, contributing to payer value propositions, payer research, objection handling, and access field tools.
• Translate clinical and economic evidence into clear payer narratives and materials that support reimbursement and patient access.
• Monitor payer, HTA, reimbursement, policy, and competitive trends and assess implications for evidence strategy and launch execution.

• Manage HEOR consultants, data partners, and agencies, including scope, deliverables, timelines, budgets, and quality.
• Own multiple concurrent projects, proactively…